Literature DB >> 17921103

Peptidomimetics in cancer chemotherapy.

C Avendaño1, J C Menéndez.   

Abstract

A summary of the current status of the application of peptidomimetics in cancer therapeutics as an alternative to peptide drugs is provided. Only compounds that are used in therapy or at least under clinical trials are discussed, using inhibitors of farnesyltransferase, proteasome and matrix metalloproteinases as examples.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17921103     DOI： 10.1007/s12094-007-0104-6

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


  29 in total

1.  Convergent solutions to binding at a protein-protein interface.

Authors:  W L DeLano; M H Ultsch; A M de Vos; J A Wells
Journal:  Science       Date:  2000-02-18       Impact factor: 47.728

Review 2.  The ubiquitin-proteasome pathway and proteasome inhibitors.

Authors:  J Myung; K B Kim; C M Crews
Journal:  Med Res Rev       Date:  2001-07       Impact factor: 12.944

Review 3.  Matrix metalloprotease inhibitors: design from structure.

Authors:  N Borkakoti
Journal:  Biochem Soc Trans       Date:  2004-02       Impact factor: 5.407

Review 4.  Inhibitors of farnesyltransferase: a rational approach to cancer chemotherapy?

Authors:  Ian M Bell
Journal:  J Med Chem       Date:  2004-04-08       Impact factor: 7.446

Review 5.  Ras farnesyltransferase: a new therapeutic target.

Authors:  D M Leonard
Journal:  J Med Chem       Date:  1997-09-12       Impact factor: 7.446

Review 6.  Farnesyl transferase inhibitors: a novel targeted tnerapy for cancer.

Authors:  S R Johnston
Journal:  Lancet Oncol       Date:  2001-01       Impact factor: 41.316

Review 7.  Ras signaling pathway proteins as therapeutic targets.

Authors:  A A Adjei
Journal:  Curr Pharm Des       Date:  2001-11       Impact factor: 3.116

8.  Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer.

Authors:  Donald Bissett; Ken J O'Byrne; J von Pawel; Ulrich Gatzemeier; Allan Price; Marianne Nicolson; Richard Mercier; Elva Mazabel; Carol Penning; Min H Zhang; Mary A Collier; Frances A Shepherd
Journal:  J Clin Oncol       Date:  2005-02-01       Impact factor: 44.544

9.  Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids.

Authors:  J Adams; M Behnke; S Chen; A A Cruickshank; L R Dick; L Grenier; J M Klunder; Y T Ma; L Plamondon; R L Stein
Journal:  Bioorg Med Chem Lett       Date:  1998-02-17       Impact factor: 2.823

10.  Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy.

Authors:  Mario Boccadoro; Gareth Morgan; Jamie Cavenagh
Journal:  Cancer Cell Int       Date:  2005-06-01       Impact factor: 5.722
View more
  2 in total

1.  Exploring novel strategies for AIDS protozoal pathogens: α-helix mimetics targeting a key allosteric protein-protein interaction in C. hominis TS-DHFR.

Authors:  W Edward Martucci; Johanna M Rodriguez; Melissa A Vargo; Matthew Marr; Andrew D Hamilton; Karen S Anderson
Journal:  Medchemcomm       Date:  2013-09       Impact factor: 3.597

2.  Synthesis of P,N-heterocycles from omega-amino-H-phosphinates: conformationally restricted alpha-amino acid analogs.

Authors:  Clémence Queffelec; Patrice Ribière; Jean-Luc Montchamp
Journal:  J Org Chem       Date:  2008-10-15       Impact factor: 4.354
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.